EP1257565A4 - Mucin-1 derived antigens and their use in immunotherapy - Google Patents

Mucin-1 derived antigens and their use in immunotherapy

Info

Publication number
EP1257565A4
EP1257565A4 EP01902160A EP01902160A EP1257565A4 EP 1257565 A4 EP1257565 A4 EP 1257565A4 EP 01902160 A EP01902160 A EP 01902160A EP 01902160 A EP01902160 A EP 01902160A EP 1257565 A4 EP1257565 A4 EP 1257565A4
Authority
EP
European Patent Office
Prior art keywords
mucin
immunotherapy
derived antigens
antigens
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01902160A
Other languages
German (de)
French (fr)
Other versions
EP1257565A1 (en
Inventor
Ian F C Mckenzie
Geoff A Pietersz
Vasso Apostolopoulous
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Austin Research Institute
Original Assignee
Austin Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPQ5369A external-priority patent/AUPQ536900A0/en
Priority claimed from US09/593,870 external-priority patent/US6548643B1/en
Application filed by Austin Research Institute filed Critical Austin Research Institute
Publication of EP1257565A1 publication Critical patent/EP1257565A1/en
Publication of EP1257565A4 publication Critical patent/EP1257565A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP01902160A 2000-02-01 2001-02-01 Mucin-1 derived antigens and their use in immunotherapy Withdrawn EP1257565A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPQ536900 2000-02-01
AUPQ5369A AUPQ536900A0 (en) 2000-02-01 2000-02-01 Antigens and their use in immunotherapy
US593870 2000-06-14
US09/593,870 US6548643B1 (en) 1994-11-16 2000-06-14 Antigen carbohydrate compounds and their use in immunotherapy
PCT/AU2001/000090 WO2001057068A1 (en) 2000-02-01 2001-02-01 Mucin-1 derived antigens and their use in immunotherapy

Publications (2)

Publication Number Publication Date
EP1257565A1 EP1257565A1 (en) 2002-11-20
EP1257565A4 true EP1257565A4 (en) 2005-04-06

Family

ID=25646253

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01902160A Withdrawn EP1257565A4 (en) 2000-02-01 2001-02-01 Mucin-1 derived antigens and their use in immunotherapy

Country Status (4)

Country Link
EP (1) EP1257565A4 (en)
JP (1) JP2003533181A (en)
CA (1) CA2399026A1 (en)
WO (1) WO2001057068A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ797700A0 (en) 2000-06-06 2000-06-29 Austin Research Institute, The Vaccine
EP1354196B1 (en) * 2000-11-27 2010-09-15 Minerva Biotechnologies Corporation Diagnostics, drug screening and treatment for cancer
EP1288292A1 (en) * 2001-08-31 2003-03-05 Leids Universitair Medisch Centrum Long peptides of 22-40 amino acid residues that induce and/or enhance antigen specific immune responses.
JP4276432B2 (en) 2000-12-22 2009-06-10 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド Method for regulating cell growth by MUC1
PL206976B1 (en) 2001-02-20 2010-10-29 Ortho Mcneil Pharm Inc A cell therapy method for the treatment of tumors
US20040071671A1 (en) 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
GB0212046D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
GB0212036D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
US20060142546A1 (en) * 2002-09-05 2006-06-29 Franz-Georg Hanisch Immunogenic muc1 glycopeptides
GB0304634D0 (en) * 2003-02-28 2003-04-02 Glaxo Group Ltd Vaccines
US7696306B2 (en) 2003-07-11 2010-04-13 Board of Agents of the University of Nebraska Compositions and methods for preventing or treating cancer
GB0321614D0 (en) * 2003-09-15 2003-10-15 Glaxo Group Ltd Vaccines
WO2005042573A1 (en) * 2003-10-24 2005-05-12 Dana-Farber Cancer Institute, Inc. Modulation of the interaction of muc1 with muc1 ligands
JP4549666B2 (en) * 2003-12-12 2010-09-22 タカラバイオ株式会社 Antibody production method
JP2008528623A (en) * 2005-01-28 2008-07-31 ラモット アット テル アビブ ユニバーシティ， リミテッド Α / β antibody of anti-MUC1
DK1764372T3 (en) * 2005-09-20 2009-11-30 Peter Jon Nelson Tissue inhibitor of metalloproteinases (TIMP) bound to glycosylphosphatidylinositol (GPI) anchors for cancer treatment
WO2008011672A1 (en) 2006-07-25 2008-01-31 4G Vaccines Pty Ltd A cancer vaccine comprising a mucin 1 (muc1) t cell epitope-derived peptide
WO2008097840A2 (en) 2007-02-02 2008-08-14 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of muc1 by hsf1 and stat3
WO2008097844A2 (en) 2007-02-02 2008-08-14 Dana -Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
JP5971945B2 (en) * 2008-04-17 2016-08-17 ピーディーエス バイオテクノロジー コーポレイションＰｄｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Stimulation of immune responses by enantiomers of cationic lipids
PT2352508E (en) 2008-10-17 2014-05-26 Genus Oncology Llc Muc-1 cytoplasmic domain peptides as inhibitors of cancer
JP5702371B2 (en) 2009-05-27 2015-04-15 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Inhibition of inflammation using antagonists of MUC1
WO2011100688A1 (en) 2010-02-12 2011-08-18 Dana-Farber Cancer Institute, Inc. Improved antagonists of muc1
US9597392B2 (en) 2010-05-10 2017-03-21 Ascend Biopharmaceuticals Pty Ltd. Use of high molecular weight mannan for inducing and/or enhancing an immune response
US9044421B2 (en) 2012-03-28 2015-06-02 Genus Oncology, Llc Treating MUC1-expressing cancers with combination therapies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006723A1 (en) * 1998-07-30 2000-02-10 Yeda Research And Development Company Ltd At The Weizmann Institute Of Science Tumor associated antigen peptides and use of same as anti-tumor vaccines
WO2001018035A2 (en) * 1999-09-08 2001-03-15 Transgene S.A. Muc-1 derived peptides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8929097D0 (en) * 1989-12-22 1990-02-28 Imp Cancer Res Tech Mucin nucleotides
AUPM322393A0 (en) * 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
IL110464A0 (en) * 1994-07-26 1994-10-21 Univ Ramot Novel proteins for the diagnosis, imaging, and therapy of human cancer
AUPN568095A0 (en) * 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
CA2282300C (en) * 1997-02-24 2011-08-02 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen
IT1303683B1 (en) * 1998-10-30 2001-02-23 Menarini Ricerche Spa PHARMACEUTICAL COMPOSITION WITH ANTI-TUMORAL ACTION CONTAINING DNACODIFIER FOR FRAGMENTS OF AN ANTIGENIC PROTEIN.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006723A1 (en) * 1998-07-30 2000-02-10 Yeda Research And Development Company Ltd At The Weizmann Institute Of Science Tumor associated antigen peptides and use of same as anti-tumor vaccines
WO2001018035A2 (en) * 1999-09-08 2001-03-15 Transgene S.A. Muc-1 derived peptides

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
APOSTOLOPOULOS V ET AL: "MUC1 AND BREAST CANCER", CURRENT OPINION IN MOLECULAR THERAPEUTICS, CURRENT DRUGS, LONDON,, GB, vol. 1, no. 1, February 1999 (1999-02-01), pages 98 - 103, XP001097590, ISSN: 1464-8431 *
BROSSART P ET AL: "Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies", BLOOD, W.B.SAUNDERS COMPAGNY, ORLANDO, FL, US, vol. 93, no. 12, 15 June 1999 (1999-06-15), pages 4309 - 4317, XP002147432, ISSN: 0006-4971 *
CARMON L ET AL: "NOVEL BREAST-TUMOR-ASSOCIATED MUCI-DERIVED PEPTIDES: CHARACTERIZATION IN DB-/- X BETA2 MICROGLOBULIN (BETA2M) NULL MICE TRANSGENIC FOR A CHIMERIC HLA-A2.1/DB-BETA2 MICROGLOBULIN SINGLE CHAIN", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 85, no. 3, 2000, pages 391 - 397, XP001009767, ISSN: 0020-7136 *
See also references of WO0157068A1 *
VAUGHAN H A ET AL: "Induction of humoral and cellular responses in cynomolgus monkeys immunised with mannan-human MUC1 conjugates", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 17, no. 20-21, 4 June 1999 (1999-06-04), pages 2740 - 2752, XP004169689, ISSN: 0264-410X *
ZRIHAN-LICHT S ET AL: "CHARACTERIZATION AND MOLECULAR CLONING OF A NOVEL MUC1 PROTEIN, DEVOID OF TANDEM REPEATS, EXPRESSED IN HUMAN BREAST CANCER TISSUE", EUROPEAN JOURNAL OF BIOCHEMISTRY, BERLIN, DE, vol. 224, no. 2, 1 September 1994 (1994-09-01), pages 787 - 795, XP000575936, ISSN: 0014-2956 *

Also Published As

Publication number Publication date
EP1257565A1 (en) 2002-11-20
CA2399026A1 (en) 2001-08-09
WO2001057068A1 (en) 2001-08-09
JP2003533181A (en) 2003-11-11

Similar Documents

Publication Publication Date Title
EP1257565A4 (en) Mucin-1 derived antigens and their use in immunotherapy
HK1208705A1 (en) Multivalent antibodies and uses therefor
AU4976001A (en) Mucin-1 specific binding members and methods of use thereof
HUP0501113A2 (en) Cripto blocking antibodies and uses thereof
GB0023008D0 (en) Improvements in vaccination
HUP0301076A3 (en) Linezolid-crystal form ii and preparation thereof
GB9806666D0 (en) Antigen preparation and use
AU2002243363A1 (en) Use of aziridino-compounds in the treatment of immune dysfunctions
HK1042020A1 (en) Cup product for use in brassiere and brassiere using the cup product
IL150679A0 (en) Use of mia in immunotherapy
EP1316560A4 (en) Novel human cancer/testis antigen and gene thereof
AU2003267361A8 (en) Orthopoxvirus antigens and use thereof
GB0026134D0 (en) Peptides and their use
GB0105606D0 (en) Immunogens and vaccines and their preparation and use
AU2001261534A1 (en) The meca-79 antigen and related methods
IL154297A0 (en) Glycoproteins, their preparation and use
AUPQ536900A0 (en) Antigens and their use in immunotherapy
EP1264600A4 (en) Immune enhancement compositions and use thereof
GB0200843D0 (en) Benzodioxinopyrroles their preparation and use
IL158573A0 (en) Cripto blocking antibodies and uses thereof
EP1437367A4 (en) Antibody and use thereof
GB0014191D0 (en) Use and combined preparation
AU7660601A (en) Pseudo-metalloproteins, their preparation and use
GB0021187D0 (en) Acylase and its use
GB0026428D0 (en) Hydroimidazolone derivatives and their use in therapy

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020830

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050221

17Q First examination report despatched

Effective date: 20050517

17Q First examination report despatched

Effective date: 20050517

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120901